中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展

doi:10.12114/j.issn.1007-9572.2020.00.096

摘要/Abstract

摘要： 近年来心脏标志物领域有了飞速的发展，推动了整体心血管疾病诊断水平的提高。研究表明，中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为急性肾损伤（AKI）的一种标志物，与冠心病患者疾病的严重程度、不良预后及未来心血管事件的发生相关，是冠心病领域的潜力标志物。本文就NGAL的来源与性质及NGAL与冠状动脉病变严重程度、稳定型冠心病、急性冠脉综合征（ACS）、未来冠心病事件的关系的研究进展做一综述，希望能够为冠心病生物标志物领域的研究提供新的参考方向。

关键词: 冠心病, 中性粒细胞明胶酶相关脂质运载蛋白, 生物标志物, 冠状动脉病变, 稳定型冠心病, 急性冠脉综合征, 未来冠心病事件

Abstract: In recent years，the rapid development of cardiac markers has improved the overall level of cardiovascular disease's diagnosis.Research findings have shown that neutrophil gelatinase-associated lipocalin（NGAL），as a marker of acute renal injury（AKI），is closely related to the severity of coronary heart disease，adverse prognosis and the occurrence of future cardiovascular events.NGAL is also a potential marker in coronary heart disease.The purpose of this review is to elucidate the origin and nature of NGAL and the relationship between NGAL and the severity of coronary artery disease，stable coronary heart disease，acute coronary syndrome（ACS）and future coronary heart disease events.And it aims to provide a promising reference direction for the researches of biomarkers in coronary heart disease.

Key words: Coronary disease, Neutrophil gelatinase-associated lipocalin, Biomarkers, Coronary artery disease, Stable coronary heart disease, Acute coronary syndrome, Future coronary heart disease events

崔小豪,杨志明. 中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展[J]. 中国全科医学, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.
CUI Xiaohao,YANG Zhiming. Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease　[J]. Chinese General Practice, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.

参考文献

［1］PIEPOLI M F，CORRà U，DENDALE P，et al．Challenges in secondary prevention after acute myocardial infarction：a call for action［J］．Eur J Cardiovasc Nurs，2017，16（5）：369-380．DOI：10.1177/1474515117702594.
［2］KHAWAJA S，JAFRI L，SIDDIQUI I，et al．The utility of neutrophil gelatinase-associated Lipocalin（NGAL）as a marker of acute kidney injury（AKI）in critically ill patients［J］．Biomark Res，2019，7：4．DOI：10.1186/s40364-019-0155-1.
［3］KJELDSEN L，JOHNSEN A H，SENGEL?V H，et al．Isolation and primary structure of NGAL，a novel protein associated with human neutrophil gelatinase［J］．J Biol Chem，1993，268（14）：10425-10432.
［4］PEDERSEN K R，RAVN H B，HJORTDAL V E，et al．Neutrophil gelatinase-associated lipocalin（NGAL）：validation of commercially available ELISA［J］．Scand J Clin Lab Invest，2010，70（5）：374-382．DOI：10.3109/00365513.2010.486868.
［5］HELANOVA K，SPINAR J，PARENICA J.Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin（NGAL）in patients with cardiovascular diseases——review［J］．Kidney Blood Press Res，2014，39（6）：623-629．DOI：10.1159/000368474.
［6］PRECEK J，HUTYRA M，KOVáCIK F，et al．Biomarkers of renal function in prognostic stratification of patients with acute coronary syndrome［J］．Cor Vasa，2018，60（2）：e148-154．DOI：10.1016/j.crvasa.2017.05.018.
［7］HEMDAHL A L，GABRIELSEN A，ZHU C Y，et al．Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction［J］．Arterioscler Thromb Vasc Biol，2006，26（1）：136-142．DOI：10.1161/01.ATV.0000193567.88685.f4.
［8］EILENBERG W，STOJKOVIC S，PIECHOTA-POLANCZYK A，et al．Neutrophil gelatinase-associated lipocalin（NGAL）is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro［J］．Eur J Vasc Endovasc Surg，2016，51（5）：623-631．DOI：10.1016/j.ejvs.2016.01.009.
［9］SUNG H K，CHAN Y K，HAN M，et al．Lipocalin-2（NGAL）attenuates autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia［J］．J Cell Physiol，2017，232（8）：2125-2134．DOI：10.1002/jcp.25672.
［10］ZOGRAFOS T，HALIASSOS A，KOROVESIS S，et al．Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease［J］．Am J Cardiol，2009，104（7）：917-920．DOI：10.1016/j.amjcard.2009.05.023.
［11］SOYLU K，AKSAN G，NAR G，et al．Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome［J］．Anatol J Cardiol，2015，15（6）：450-455．DOI：10.5152/akd.2014.5513.
［12］KATAGIRI M，TAKAHASHI M，DOI K，et al．Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease［J］．Heart Vessels，2016，31（10）：1595-1602．DOI：10.1007/s00380-015-0776-8.
［13］李超，彭瑜，高涵翔，等．血浆中性粒细胞明胶酶相关脂质运载蛋白水平与急性ST段抬高型心肌梗死病变严重程度的关系［J］．中国循环杂志，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
LI C，PENG Y，GAO H X，et al．Relationship between plasma level of neutrophil gelatinase-associated lipocalin and coronary lesion severity in patients with acute ST-elevation myocardial infarction［J］．Chinese Circulation Journal，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
［14］MALYSZKO J，BACHORZEWSKA-GAJEWSKA H，MALYSZKO J S，et al．Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease［J］．Nephrology（Carlton），2008，13（2）：153-156．DOI：10.1111/j.1440-1797.2007.00899.x.
［15］PAULSSON J，DADFAR E，HELD C，et al．Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease［J］．Atherosclerosis，2007，192（2）：328-334．DOI：10.1016/j.atherosclerosis.2006.08.003.
［16］CHAKRABARTI S，PATEL K D.Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils［J］．J Leukoc Biol，2005，78（1）：279-288．DOI：10.1189/jlb.1004612.
［17］SIVALINGAM Z，ERIK MAGNUSSON N，GROVE E L，et al．Neutrophil gelatinase-associated lipocalin（NGAL）and cardiovascular events in patients with stable coronary artery disease［J］．Scand J Clin Lab Invest，2018，78（6）：470-476．DOI：10.1080/00365513.2018.1499956.
［18］LINDBERG S，PEDERSEN S H，MOGELVANG R，et al．Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention［J］．J Am Coll Cardiol，2012，60（4）：339-345．DOI：10.1016/j.jacc.2012.04.017.
［19］ZYKOV M V，KASHTALAP V V，BYKOVA I S，et al．Clinical and prognostic value of serum neutrophil gelatinase-associated lipocalin in patients with ST-segment elevation myocardial infarction［J］．Kardiologiia，2016，56（5）：24-29．DOI：10.18565/cardio.2016.5.24-29.
［20］LIM Y M，MOON J Y，MIN D，et al．Serial measurements of neutrophil gelatinase-associated lipocalin：prognostic value in patients with ST-segment elevation myocardial infarction treated with a primary percutaneous coronary intervention［J］．Coron Artery Dis，2017，28（8）：690-696．DOI：10.1097/MCA.0000000000000542.
［21］FAN Y，ZOU C.Prognostic value of neutrophil gelatinase-associated lipocalin in patients with acute ST-segment elevation myocardial infarction：a meta-analysis［J］．Eur J Prev Cardiol，2019，26（4）：444-446．DOI：10.1177/2047487318783254.
［22］NYMO S H，HARTFORD M，UELAND T，et al．Serum neutrophil gelatinase-associated lipocalin（NGAL）concentration is independently associated with mortality in patients with acute coronary syndrome［J］．Int J Cardiol，2018，262：79-84．DOI：10.1016/j.ijcard.2018.03.028.
［23］LAHIRI A，ALEX A G，GEORGE P V.Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes［J］．Indian Heart J，2018，70（2）：220-224．DOI：10.1016/j.ihj.2017.06.005.
［24］SHALENKOVA M A，MIKHAILOVA Z D，KLIMKIN P F.NGAL as a marker for some extrarenal complications in acute coronary syndrome［J］．Kardiologiia，2018（S3）：19-26.
［25］MARTíNEZ-MARTíNEZ E，BUONAFINE M，BOUKHALFA I，et al．Aldosterone target NGAL（neutrophil gelatinase-associated lipocalin）is involved in cardiac remodeling after myocardial infarction through NFκB pathway［J］．Hypertension，2017，70（6）：1148-1156．DOI：10.1161/HYPERTENSIONAHA.117.09791.
［26］NAKA K K，PAPATHANASSIOU K，BECHLIOULIS A，et al．Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus［J］．Clin Biochem，2018，53：31-37．DOI：10.1016/j.clinbiochem.2017.12.010.
［27］CHONG J J H，PRINCE R L，THOMPSON P L，et al．Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women［J］．J Am Heart Assoc，2019，8（1）：e011028．DOI：10.1161/JAHA.118.011028.
［28］FASSETT R G，ROBERTSON I K，BALL M J，et al．Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease：a post hoc analysis of the LORD trial［J］．Nephrol Dial Transplant，2012，27（1）：182-189．DOI：10.1093/ndt/gfr193.
［29］LáBR K，?PINAR J，PARENICA J，et al．Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin［J］．Kidney Blood Press Res，2018，43（6）：1865-1877．DOI：10.1159/000495819.
［30］CHEN S，CHEN X C，LOU X H，et al．Determination of serum neutrophil gelatinase-associated lipocalin as a prognostic biomarker of acute spontaneous intracerebral hemorrhage［J］．Clin Chim Acta，2019，492：72-77．DOI：10.1016/j.cca.2019.02.009.
［31］MOSCHEN A R，ADOLPH T E，GERNER R R，et al．Lipocalin-2：a master mediator of intestinal and metabolic inflammation［J］．Trends Endocrinol Metab，2017，28（5）：388-397．DOI：10.1016/j.tem.2017.01.003.
［61］MATSUSHITA S，YONEKURA K，MERA K，et al．Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy［J］．J Dermatol，2011，38（10）：996-998．DOI:10.1111/j.1346-8138.2010.01149.x.
［62］BELEZNAY K M，LEVESQUE M A，GILL S.Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain［J］．Curr Oncol，2009，16（5）：81-83．DOI:10.3747/co.v16i5.374.
［63］TAKAHAGI S，NODA H，KAMEGASHIRA A，et al．Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy［J］．J Dermatol，2009，36（8）：457-461．DOI:10.1111/j.1346-8138.2009.00676.x.
［64］MOCHITOMI Y，SAKAMOTO R，GUSHI A，et al．Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy：report of two cases［J］．J Dermatol，2005，32（8）：632-637．DOI:10.1111/j.1346-8138.2005.tb00812.x.
［65］WATANABE Y，HOSHIAI H，UEDA H，et al．Low-dose mitomycin C，etoposide，and cisplatin for invasive vulvar Paget's disease［J］．Int J Gynecol Cancer，2002，12（3）：304-307．DOI:10.1046/j.1525-1438.2002.01126.x.
［66］AL HALLAK M N，ZOUAIN N.Extramammary perianal Paget's disease［J］．Case Rep Gastroenterol，2009，3（3）：332-337．DOI:10.1159/000256382.
［67］ZOLLO J D，ZEITOUNI N C.The Roswell park cancer institute experience with extramammary Paget's disease［J］．Br J Dermatol，2000，142（1）：59-65．DOI:10.1046/j.1365-2133.2000.03242.x.
［68］YE J N，RHEW D C，YIP F，et al．Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid：a case report［J］．Cutis，2006，77（4）：245-250.
［69］ITO T，KAKU Y，NAGAE K，et al．Tumor thickness as a prognostic factor in extramammary Paget's disease［J］．J Dermatol，2015，42（3）：269-275．DOI:10.1111/1346-8138.12764.
［70］KARAM A，DORIGO O.Treatment outcomes in a large cohort of patients with invasive extramammary Paget's disease［J］．Gynecol Oncol，2012，125（2）：346-351．DOI:10.1016/j.ygyno.2012.01.032.
［71］HERREL L A 1，WEISS A D，GOODMAN M，et al．Extramammary Paget's disease in males:survival outcomes in 495 patients［J］.Ann Surg Oncol，2015，22（5）:1625-1630．DOI：10.1245/s10434-014-4139-y.
［72］WANG Z，LU M，DONG G Q，et al．Penile and scrotal Paget's disease:130 Chinese patients with long-term follow-up［J］.BJU Int，2008，102（4）：485-488．DOI:10.1111/j.1464-410X.2008.07575.x.

[1]	王秋实, 李虹伟. CHA₂DS₂-VASc卒中风险评分对冠心病三支血管或左主干病变患者主要不良心血管事件的预测价值研究[J]. 中国全科医学, 2023, 26(33): 4130-4136.
[2]	袁德慧, 李玉红, 熊敏, 俞敏, 马瑞亮, 杨方方, 俞巧稚, 王明欢. 妊娠女性不同时期非稳态负荷状况及其影响因素研究[J]. 中国全科医学, 2023, 26(32): 4057-4063.
[3]	李懿茹, 李玉红. 非稳态负荷的评估方法及其对健康影响的研究新进展[J]. 中国全科医学, 2023, 26(32): 4051-4056.
[4]	袁铭培, 林耀望, 贝伟杰, 刘华东, 董少红, 孙鑫. 经远端桡动脉入径逆向开通闭塞桡动脉的可行性：单中心前瞻性研究[J]. 中国全科医学, 2023, 26(27): 3373-3377.
[5]	蔡高军, 师干伟, 李峰, 李文华, 严永敏, 薛社亮, 肖建强, 顾君, 宋艳斌, 张刘燕, 卢伟, 龚春. 如何提高经远端桡动脉入径穿刺成功率、"曲径通幽"？基于两千余病例的经验总结[J]. 中国全科医学, 2023, 26(27): 3361-3365.
[6]	刘明浩, 王攀, 高立建, 徐淑清, 王欢欢, 赵光贤, 陈珏, 乔树宾, 徐波, 袁晋青. 经远端桡动脉入径行二次经皮冠状动脉介入治疗的可行性、安全性和手术时机研究[J]. 中国全科医学, 2023, 26(27): 3366-3372.
[7]	兰永昊, 科尔沁, 韩蕊, 梅迎晨, 刘巍. 经远端桡动脉入径行经皮冠状动脉介入治疗：优势、劣势、机遇和挑战[J]. 中国全科医学, 2023, 26(27): 3355-3360.
[8]	闫海浩, 张飞飞, 党懿. 残余胆固醇与急性冠脉综合征患者易损斑块特征的相关性研究[J]. 中国全科医学, 2023, 26(26): 3303-3307.
[9]	祖姆热提·阿布都克依木, 马燕玲, 朱凯瑞, 刘芳, 李霞. 早期生长反应因子3和白介素6水平与冠状动脉粥样硬化性心脏病的相关性研究[J]. 中国全科医学, 2023, 26(24): 3016-3021.
[10]	徐婷, 季明辉, 陈一萌, 高瑜, 朱涵菲, 丁玲玉, 许勤. 基于多组学的老年衰弱人群生物标志物研究[J]. 中国全科医学, 2023, 26(23): 2871-2876.
[11]	王丹, 王建辉, 董建秀, 常文红, 秦璐, 刘琪, 陈晨. 基于网络干预对经皮冠状动脉介入治疗术后患者运动行为的影响研究[J]. 中国全科医学, 2023, 26(21): 2603-2608.
[12]	刘晶涛, 苏荷, 秦小金, 兰云霞, 张金枝. 冠心病患者心脏康复相关指南的系统评价[J]. 中国全科医学, 2023, 26(19): 2323-2331.
[13]	高扬, 王贇霞, 高传玉. ≤45岁急性冠脉综合征患者可能家族性高胆固醇血症的临床特点及血脂达标影响因素研究[J]. 中国全科医学, 2023, 26(18): 2232-2237.
[14]	苟登群, 张鹭, 徐元锂, 蒋明娇, 吴和梅, 陶明. 中性粒细胞与淋巴细胞比值和红细胞分布宽度作为衰弱潜在生物标志物的范围综述[J]. 中国全科医学, 2023, 26(17): 2169-2175.
[15]	徐迪, 田金萍, 刘赟玥, 薛冷, 张林, 孙国珍, 王连生, 徐晶晶. 冠心病合并2型糖尿病患者经皮冠状动脉介入治疗围术期血糖波动的特点及影响因素研究[J]. 中国全科医学, 2023, 26(15): 1863-1872.